VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst
Source: SeekingAlpha
2026-02-28 05:11:55 ET
...
Read the full article on Seeking Alpha
For further details see:
VTv Therapeutics: Cadisegliatin's Phase 3 CATT1 Readout Is The Next Catalyst
vTv Therapeutics Inc.
NASDAQ: VTVT
VTVT Trading
-4.98% G/L:
$34.27 Last:
92,673 Volume:
$38.44 Open:
VTVT Latest News
March 10, 2026 04:01:00 pm
vTv Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 02, 2026 08:00:00 am
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
VTVT Stock Data
$142,860,345
3,772,852
N/A
23
N/A
Biotechnology & Life Sciences
Healthcare
US
High Point
